Hansoh Biomedical R&d Company

This study tests a new drug called HS-20122 in combination with other cancer medicines for people with advanced non-small cell lung cancer. The trial includes three different drug combinations depending on the patient's tumor type. The main goals are to check safety, find the bes…

This Phase 3 trial tests a new drug called HS-20093 against standard chemotherapy in 494 people with advanced esophageal cancer that has worsened after initial treatment. The goal is to see if HS-20093 helps people live longer and controls the tumor better. Participants will rece…

This phase 3 study tests whether a new combination of drugs (HS-20093 plus adebrelimab) works better than the standard chemotherapy docetaxel for people with advanced or metastatic non-squamous non-small cell lung cancer that has already been treated. The trial plans to enroll 45…